Crinetics Pharmaceuticals CRNX Stock
Crinetics Pharmaceuticals Price Chart
Crinetics Pharmaceuticals CRNX Financial and Trading Overview
| Crinetics Pharmaceuticals stock price | 44.02 USD |
| Previous Close | 20.39 USD |
| Open | 20.33 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 1100 |
| Day's Range | 20.15 - 20.84 USD |
| 52 Week Range | 15.23 - 24.58 USD |
| Volume | 307.47K USD |
| Avg. Volume | 466.02K USD |
| Market Cap | 1.12B USD |
| Beta (5Y Monthly) | 0.94084 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.69 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.89 USD |
CRNX Valuation Measures
| Enterprise Value | 877.45M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.7375693 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 261.87213 |
| Price/Book (mrq) | 4.0003853 |
| Enterprise Value/Revenue | 204.771 |
| Enterprise Value/EBITDA | -4.848 |
Trading Information
Crinetics Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.94084 |
| 52-Week Change | 13.55% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 24.58 USD |
| 52 Week Low | 15.23 USD |
| 50-Day Moving Average | 20.31 USD |
| 200-Day Moving Average | 18.83 USD |
CRNX Share Statistics
| Avg. Volume (3 month) | 466.02K USD |
| Avg. Daily Volume (10-Days) | 391.99K USD |
| Shares Outstanding | 54.03M |
| Float | 42.45M |
| Short Ratio | 5.28 |
| % Held by Insiders | 2.90% |
| % Held by Institutions | 106.22% |
| Shares Short | 3.29M |
| Short % of Float | 6.98% |
| Short % of Shares Outstanding | 6.09% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -4248.14% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -35.15% |
| Return on Equity (ttm) | -60.094% |
Income Statement
| Revenue (ttm) | 4.29M USD |
| Revenue Per Share (ttm) | 0.08 USD |
| Quarterly Revenue Growth (yoy) | -14.39% |
| Gross Profit (ttm) | -125488000 USD |
| EBITDA | -181007008 USD |
| Net Income Avi to Common (ttm) | -175286000 USD |
| Diluted EPS (ttm) | -3.22 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 296.12M USD |
| Total Cash Per Share (mrq) | 5.48 USD |
| Total Debt (mrq) | 2.82M USD |
| Total Debt/Equity (mrq) | 1.01 USD |
| Current Ratio (mrq) | 11.603 |
| Book Value Per Share (mrq) | 5.192 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -142380000 USD |
| Levered Free Cash Flow (ttm) | -78527624 USD |
Profile of Crinetics Pharmaceuticals
| Country | United States |
| State | CA |
| City | San Diego |
| Address | Building No. 2 |
| ZIP | 92121 |
| Phone | 858 450 6464 |
| Website | https://www.crinetics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 210 |
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.
Q&A For Crinetics Pharmaceuticals Stock
What is a current CRNX stock price?
Crinetics Pharmaceuticals CRNX stock price today per share is 44.02 USD.
How to purchase Crinetics Pharmaceuticals stock?
You can buy CRNX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Crinetics Pharmaceuticals?
The stock symbol or ticker of Crinetics Pharmaceuticals is CRNX.
Which industry does the Crinetics Pharmaceuticals company belong to?
The Crinetics Pharmaceuticals industry is Biotechnology.
How many shares does Crinetics Pharmaceuticals have in circulation?
The max supply of Crinetics Pharmaceuticals shares is 78.95M.
What is Crinetics Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Crinetics Pharmaceuticals PE Ratio is now.
What was Crinetics Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Crinetics Pharmaceuticals EPS is -3.69 USD over the trailing 12 months.
Which sector does the Crinetics Pharmaceuticals company belong to?
The Crinetics Pharmaceuticals sector is Healthcare.
Crinetics Pharmaceuticals CRNX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}